Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]
Islet amyloid polypeptide, islet amyloid, and diabetes mellitus
Among products found be accurately labeled (all of which also passed our tests for contamination with heavy metals such as lead), we selected for glutathione overall, liposomal glutathione, and S-acetyl glutathione, each representing high quality, transparent labeling, and lower cost relative to comparable products
The microbiota modulates GLP-1 secretion through microbial metabolites
Journal of Physiology (Paris), 91(3), 173178